OptimizeRx Corp. (NASDAQ:OPRX) Short Interest Down 16.4% in February

OptimizeRx Corp. (NASDAQ:OPRX) was the recipient of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 1,398,242 shares, a decrease of 16.4% from the February 12th total of 1,673,046 shares. Approximately 7.9% of the company’s stock are short sold. Based on an average daily volume of 364,058 shares, the short-interest ratio is currently 3.8 days. Based on an average daily volume of 364,058 shares, the short-interest ratio is currently 3.8 days. Approximately 7.9% of the company’s stock are short sold.

OptimizeRx Stock Up 2.7%

NASDAQ OPRX traded up $0.17 on Monday, hitting $6.57. 260,314 shares of the stock traded hands, compared to its average volume of 410,703. The company has a current ratio of 3.04, a quick ratio of 3.04 and a debt-to-equity ratio of 0.17. The stock has a 50-day moving average of $9.93 and a 200 day moving average of $14.35. OptimizeRx has a twelve month low of $5.54 and a twelve month high of $22.25. The company has a market capitalization of $123.25 million, a P/E ratio of 25.27 and a beta of 1.21.

OptimizeRx (NASDAQ:OPRX) last issued its earnings results on Saturday, January 31st. The company reported $0.51 EPS for the quarter. OptimizeRx had a return on equity of 10.61% and a net margin of 4.69%. As a group, analysts expect that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

OptimizeRx declared that its Board of Directors has initiated a stock buyback program on Thursday, March 5th that permits the company to buyback $10.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 6.8% of its stock through open market purchases. Stock buyback programs are typically a sign that the company’s board of directors believes its stock is undervalued.

Analysts Set New Price Targets

Several equities research analysts have issued reports on OPRX shares. Weiss Ratings restated a “sell (d+)” rating on shares of OptimizeRx in a report on Monday, December 22nd. Zacks Research cut OptimizeRx from a “strong-buy” rating to a “hold” rating in a research note on Monday, December 15th. B. Riley Financial reissued a “buy” rating and set a $11.00 price target (down from $28.00) on shares of OptimizeRx in a research report on Friday, March 6th. Wall Street Zen upgraded shares of OptimizeRx from a “buy” rating to a “strong-buy” rating in a research note on Sunday, December 14th. Finally, Stephens reduced their price objective on shares of OptimizeRx from $17.00 to $10.00 and set an “equal weight” rating on the stock in a research note on Friday, March 6th. Six research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, OptimizeRx has an average rating of “Moderate Buy” and a consensus price target of $17.57.

Institutional Trading of OptimizeRx

Institutional investors and hedge funds have recently modified their holdings of the business. Los Angeles Capital Management LLC bought a new position in shares of OptimizeRx in the 2nd quarter worth about $349,000. Connor Clark & Lunn Investment Management Ltd. bought a new stake in shares of OptimizeRx during the 2nd quarter valued at about $418,000. P.A.W. Capital Corp bought a new stake in shares of OptimizeRx during the 2nd quarter valued at about $675,000. Rhumbline Advisers raised its stake in OptimizeRx by 29.9% during the second quarter. Rhumbline Advisers now owns 36,082 shares of the company’s stock worth $487,000 after acquiring an additional 8,297 shares during the period. Finally, American Century Companies Inc. raised its stake in OptimizeRx by 52.5% during the second quarter. American Century Companies Inc. now owns 24,069 shares of the company’s stock worth $325,000 after acquiring an additional 8,286 shares during the period. 76.47% of the stock is owned by institutional investors and hedge funds.

OptimizeRx Company Profile

OptimizeRx, Inc is a healthcare technology company that operates a digital health network designed to facilitate communication between pharmaceutical manufacturers, payers and healthcare providers. Through its cloud-based platform, OptimizeRx delivers targeted digital interventions—such as patient savings messages, clinical content and product information—directly into electronic health record (EHR) workflows at the point of care. By integrating with leading EHR systems, the company helps life sciences organizations optimize brand engagement, improve patient adherence and support informed prescribing decisions.

The company’s core offerings include digital prescription benefit notifications, co-pay assistance alerts and real-time clinical messaging tailored to specific patient populations.